https://www.businesswire.com/news/home/20210808005031/en/Phase-III-Study-Shows-Genentechs-Polivy-Plus-R-CHP-Is-the-First-Regimen-in-20-Years-to-Significantly-Improve-Outcomes-in-Previously-Untreated-Aggressive-Form-of-Lymphoma-Compared-to-Standard-of-Care
ʂ̃TCgɃWv悤ƂĂ܂BXΏL̃NNbNĂ
UPLIFTōLȂő̌܂傤IKȉ{Ct܂I